Latest news with #iRhythmTechnologies
Yahoo
02-08-2025
- Business
- Yahoo
iRhythm Technologies Second Quarter 2025 Earnings: Beats Expectations
iRhythm Technologies (NASDAQ:IRTC) Second Quarter 2025 Results Key Financial Results Revenue: US$186.7m (up 26% from 2Q 2024). Net loss: US$14.2m (loss narrowed by 29% from 2Q 2024). US$0.44 loss per share (improved from US$0.65 loss in 2Q 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period iRhythm Technologies Revenues and Earnings Beat Expectations Revenue exceeded analyst estimates by 7.3%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Performance of the American Medical Equipment industry. The company's shares are up 23% from a week ago. Risk Analysis It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with iRhythm Technologies, and understanding this should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
01-08-2025
- Business
- Yahoo
iRhythm Technologies Inc (IRTC) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Revenue: $186.7 million, up 26.1% year-over-year. Adjusted EBITDA Margin: 8.4%, a 500 basis points improvement from the previous year. Gross Margin: 71.2%, driven by volume leverage and operational efficiencies. Adjusted Operating Expenses: $145.2 million, a 16% increase year-over-year. Adjusted Net Loss: $10.2 million or $0.32 per share, compared to $18.8 million or $0.61 per share in the previous year. Cash Position: $545.5 million in unrestricted cash on hand. Full Year 2025 Revenue Guidance: Raised to $720 million to $730 million. Full Year 2025 Adjusted EBITDA Margin Guidance: 8% to 8.5% of revenues. Warning! GuruFocus has detected 5 Warning Sign with IRTC. Release Date: July 31, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points iRhythm Technologies Inc (NASDAQ:IRTC) reported strong second-quarter results with $186.7 million in revenue, representing more than 26% year-over-year growth. The company achieved record new account openings and long-term continuous monitoring driven by innovative channel partnerships. International markets showed continued strong demand, with significant progress in the United Kingdom, Europe, and Japan. The partnership with Lucem Health aims to accelerate early detection of undiagnosed arrhythmias using AI-driven solutions. iRhythm Technologies Inc (NASDAQ:IRTC) expanded adjusted EBITDA margins by 500 basis points since Q2 of last year, demonstrating sustainable operating leverage. Negative Points The company continues to incur incremental legal and consulting fees related to FDA remediation efforts and DOJ subpoena activities. There is a potential negative impact on gross margins from tariffs, estimated to be 20 to 40 basis points for the full year. The company expects to be slightly free cash flow negative for full year 2025 due to inventory buildup and infrastructure investments. The innovative channel partners' contribution to revenue is still in the early stages and not fully predictable. The FDA warning letter and 483 observations are still pending resolution, with ongoing efforts to address these regulatory concerns. Q & A Highlights Q: Can you elaborate on the drivers behind the raised full-year guidance and the potential for outperformance? A: Quentin Blackford, President and CEO, explained that the guidance increase reflects strong momentum across the business. The core business remains the primary driver, with innovative channels contributing as well. The guidance was raised by $30 million for the year, with two-thirds attributed to the core business and the rest split between Zio AT and innovative channels. The company maintains a conservative approach to guidance, aiming for achievable targets. Q: What was the volume contribution from innovative channel partners in the quarter, and when do you expect the 40 active discussions to come online? A: Quentin Blackford stated that while they won't break out specific contributions, the innovative channel partners' volume increased from Q1. The 40 accounts in active discussions are expected to come online steadily over the year and into the next. The partnership with Lucem Health is expected to enhance these efforts by identifying patients with arrhythmias through AI. Q: Can you discuss the impact of Epic integrations on volume growth and the opportunity size? A: Quentin Blackford noted that Epic integrations have led to increased prescribing patterns, with some accounts seeing over 20% growth post-integration. The opportunity is significant, as 65% of their accounts using EMRs are Epic-related. The integration facilitates streamlined workflows and increased adoption of both Zio Monitor and Zio AT. Q: What are the key innovative partnerships driving growth, and how sustainable are the reorder rates? A: Quentin Blackford highlighted partnerships with Signify Health, CenterWell, and Oak Street as significant contributors. These partnerships are expected to provide repeat monitoring opportunities, with a focus on asymptomatic patients and those with comorbid conditions. The innovative channel partners are seen as a sustainable growth driver. Q: How is the FDA remediation process progressing, and what is the status of the Zio MCT filing? A: Quentin Blackford confirmed that all responses to the FDA have been submitted, and they are awaiting further action, including an inspection. The Zio MCT filing will proceed in parallel with the FDA remediation efforts. The company has revamped its quality management system and is committed to maintaining high standards. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31-07-2025
- Business
- Yahoo
FDA Clearance Boosts iRhythm Zio Device Innovation and Fuels Growth Potential
iRhythm Technologies, Inc. (NASDAQ:IRTC) is one of the . The FDA clearance for the Zio AT device upgrades signals the potential for further innovation and stock growth. A patient being monitored with a portable ECG device, showing the effectiveness of the company's products. Based in California, iRhythm Technologies, Inc. (NASDAQ:IRTC) is a digital healthcare company focused on transforming cardiac arrhythmia detection through wearable biosensors and cloud-based data analytics. Zio by iRhythm platform, the company's flagship product, makes use of a wearable biosensor patch and cloud-based analytics for monitoring heart rhythms for extended periods, aiding in the diagnosis of cardiac arrhythmias. iRhythm Technologies, Inc. (NASDAQ:IRTC) recently got the FDA 510(k) clearance for design modifications and labeling updates to its Zio AT device – a prescription-only mobile cardiac telemetry (MCT) system used for long-term ECG monitoring of both symptomatic and asymptomatic heart events. The clearance, effective from 2025, allows the device to remain commercially available in the U.S. Following the clearance, the company also launched Zio ECG Recording and Analysis System in Japan in May 2025, with nationwide availability anticipated by July 2025. Following these developments, Robert W. Baird maintained a Buy rating on the stock with a price target of $160. With a 1.17% uptick in its weekly performance, the stock had a closing price of $137.11 as of July 28, 2025. Insider Monkey database reported 31 hedge funds holding stakes in iRhythm Technologies, Inc. (NASDAQ:IRTC), reflecting a modest level of institutional confidence. While we acknowledge the potential of IRTC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Long Term Low Risk Stocks to Invest in and 13 Best Low Risk High Growth Stocks to Buy Disclosure. None.
Yahoo
17-07-2025
- Business
- Yahoo
iRhythm Technologies to Report Second Quarter 2025 Financial Results on July 31, 2025
SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2025 after the close of trading on Thursday, July 31, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the 'Quarterly Results' section of the company's investor website at About iRhythm Technologies, Inc. iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm's vision is to deliver better data, better insights, and better health for all. Investor Contact Stephanie Zhadkevich investors@ Media Contact Kassandra Perryirhythm@ in to access your portfolio
Yahoo
14-07-2025
- Business
- Yahoo
iRhythm (IRTC) Stock Trades Up, Here Is Why
Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) jumped 3.2% in the afternoon session after the positive sentiment from Wall Street analysts who saw further potential in the company. The digital healthcare firm has garnered a "Moderate Buy" consensus rating from analysts. Based on ten recent analyst ratings, the average twelve-month price target for iRhythm sits at $138.60, suggesting potential upside from its current trading level. Nine out of ten of these analysts rate the stock as a "Buy." This bullish stance from market experts likely reflects confidence in iRhythm's Zio service, a platform that uses wearable biosensors and cloud-based data analytics to diagnose cardiac arrhythmias. The company's focus on integrating artificial intelligence to provide clinically actionable insights for physicians positions it well within the growing digital health sector. After the initial pop the shares cooled down to $139.19, up 2.4% from previous close. Is now the time to buy iRhythm? Access our full analysis report here, it's free. iRhythm's shares are very volatile and have had 26 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. iRhythm is up 55.6% since the beginning of the year, but at $139.19 per share, it is still trading 10% below its 52-week high of $154.71 from June 2025. Investors who bought $1,000 worth of iRhythm's shares 5 years ago would now be looking at an investment worth $1,206. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
